(Q73043632)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11019836%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

title

Docetaxel effectively mobilizes peripheral blood CD34+ cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11019836%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference

H M Prince

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11019836%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

G C Toner

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11019836%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

J F Seymour

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11019836%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

D Blakey

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11019836%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

P Gates

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11019836%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

S Eerhard

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11019836%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

P Chapple

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11019836%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

D Wall

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11019836%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

M Quinn

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11019836%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

S Juneja

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11019836%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

M Wolf

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11019836%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

E H Januszewicz

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11019836%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

G Richardson

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11019836%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

J Scarlett

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11019836%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

P Briggs

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11019836%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

M Brettell

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11019836%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

D Rischin

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11019836%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

publication date

1 September 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11019836%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

31 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11019836%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11019836%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11019836%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

page(s)

483-487

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11019836%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1702540

31 October 2019

exact match

0 references

cites work

The importance of dose intensity in chemotherapy of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702540

7 January 2021

Chemotherapy dose escalation: case unproven

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702540

7 January 2021

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702540

7 January 2021

High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702540

7 January 2021

Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702540

7 January 2021

Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: Results of a phase I study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702540

7 January 2021

Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702540

7 January 2021

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702540

7 January 2021

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702540

7 January 2021

Peripheral blood CD34+ cell count reliably predicts autograft yield

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702540

7 January 2021

The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702540

7 January 2021

Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702540

7 January 2021

Comparison of COBE Spectra software version 4.7 PBSC and version 6.0 auto PBSC program

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702540

7 January 2021

Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702540

7 January 2021

Mobilization of peripheral blood stem cells with docetaxel and cyclophosphamide (CY) in patients with metastatic breast cancer: a randomized trial of 3 vs 4 g/m2 of CY

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702540

7 January 2021

Intermediate dose cyclophosphamide combined with a growth factor is a safe and effective regimen for mobilisation of peripheral blood progenitor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702540

7 January 2021

Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702540

7 January 2021

Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702540

7 January 2021

High-dose sequential chemotherapy with stem cell support for non-metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702540

7 January 2021